hepatic and biliary disorders
Metabolic Dysfunction–Associated Liver Disease (MASLD)
Treatment of MASLD
Elimination of causes and control of risk factors The only widely accepted treatment goal is to eliminate potential causes and risk factors. Such a goal may include discontinuation of drugs or toxins, weight loss, and Treatment or There are currently many emerging therapies for MASH targeting several different molecular pathways including peroxisome proliferator-activated receptor-alpha (PPAR-alpha),glucagon-like peptide-1 (GLP-1) modulators, and farnesoid X receptor (FXR) ligands. These new therapies show promise with respect to both resolution of MASH as well as reversal of preexisting fibrosis. Further study with several phase 3 clinical trials is ongoing. 